NCT04553536View on ClinicalTrials.gov

Cardiovascular Protection Conservative Effects of Esketamine Versus µ-opioid Receptor Agonists in General Anesthesia

NARecruitingINTERVENTIONAL

Enrollment

1,000

Participants

Timeline

Start Date

November 2, 2020

Primary Completion Date

June 30, 2023

Study Completion Date

January 31, 2024

Conditions

Opioid Analgesic Adverse Reaction

Interventions

DRUG

Esketamine, Sulfentanil or/and Remifentanil

The esketamine or the opioids will be intravenously injected or infused to the patients with propofol and one of the muscle relaxants to induce and maitain general anesthesia.

Trial Locations (1)

030001

RECRUITING

Zheng Guo, Taiyuan

All Listed Sponsors

lead

Second Hospital of Shanxi Medical University

OTHER